Indian stocks: Visit www.stage2stocks.com →

SCYNEXIS, Inc.

Stage 4 · Declining · week 1

As of Oct 22, 2026, SCYNEXIS is in Stage 4, the downtrend phase, now in its first week (since Oct 21, 2026). It closed at $3.81, 57.1% below its 52-week high and below its 200-day average, which is falling.

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. More about the company

$3.81
+0.26% today
$37.9M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is SCYX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 51w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 7w → S3 5w → S4 10w → S1 7w → S4 9w → S1 5w → S2 7w → S3 5w → S4 51w → S1 8w → S4 13w → S1 7w → S2 10w → S3 4w → S4 9w → S1 8w → S4 1w current
Total tracked: 166 weeks across 17 stage runs.

SCYX among Drug Manufacturers - Specialty & Generic50th of 84 by relative strength

All 84 →
Stocks in Drug Manufacturers - Specialty & Generic ranked by relative strength, with stage and one-month change
#StockStageRS1M
1CPIXStage 2 · wk 2398+6.8%
2ETONStage 2 · wk 3097−10.1%
3ANIKStage 2 · wk 1596+3.5%
4IRWDStage 3 · wk 396−16.4%
5TEVAStage 2 · wk 995+3.1%
6AMRXStage 2 · wk 1995+5.9%
7KNSAStage 2 · wk 7395+6.2%
8AMLXStage 2 · wk 1593−6.6%
…50SCYXStage 4 · wk 129−17.8%
vs 52W High
-57.1%
$3.57 lo$8.88 hi
57.1% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 1
1w13w26w
Week 1, early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-31.8%
200 DMA: $5.59 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.15x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-17.8%
3M
+2.1%
6M
-54.6%
YTD
-25.5%
1Y
-38.9%
Scan Membership
Breakout Watch
Latest: 2024-06-18
6 appearances in last 60 days. First seen: 2019-03-27.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 1 · Vol 0.15x
2026-10-21S41→4
Wk 1 · Vol 0.26x
2026-10-20S1
Wk 8 · Vol 0.20x
2026-10-19S1
Wk 8 · Vol 0.28x
2026-10-16S1
Wk 8 · Vol 0.71x
2026-10-15S1
Wk 8 · Vol 0.26x
2026-10-14S1
Wk 7 · Vol 0.16x
2026-10-13S1
Wk 7 · Vol 0.24x
2026-10-12S1
Wk 7 · Vol 0.20x
2026-10-09S1
Wk 7 · Vol 0.35x
2026-10-08S1
Wk 7 · Vol 1.03x
2026-10-07S1
Wk 6 · Vol 0.24x
Moving averages & range
50 DMA
$4.72
200 DMA
$5.59
52W High
$8.88
52W Low
$3.57
5D Low
$3.66
Resistance levels (recent highs)
20d High
$5.37
60d High
$5.67
120d High
$7.87
250d High
$8.88
Next resistance
+40.9%
to 20d High
ROE
-18.4%
Profit margin -53.3%
Dividend Yield
0.00%
P/B 0.6

SCYNEXIS: quick answers

What stage is SCYNEXIS in?

As of Oct 22, 2026, SCYNEXIS (SCYX) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 21, 2026 and is in its first week there. What the four stages mean

Is SCYNEXIS in an uptrend?

No. SCYNEXIS is in a Stage 4 downtrend. It trades 31.8% below its 200-day average, which is falling.

How far is SCYNEXIS from its 52-week high?

SCYNEXIS closed at $3.81 on Oct 22, 2026, 57.1% below its 52-week high of $8.88. Its 52-week low is $3.57.

How has SCYNEXIS performed over the past year?

As of Oct 22, 2026, SCYNEXIS is down 38.9% over the past year and down 25.5% so far in 2026.

Which sector and industry is SCYNEXIS in?

SCYNEXIS is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.

About this companyHealth Care· Drug Manufacturers - Specialty & Generic

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.